C W Spearman
Overview
Explore the profile of C W Spearman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gunter H, Tatz G, Maartens G, Spearman C, Mehta U, Cohen K
Pharmacoepidemiol Drug Saf
. 2024 Oct;
33(10):e5883.
PMID: 39385723
Purpose: We compared performance of the Roussel Uclaf Causality Assessment Method (RUCAM) with multidisciplinary expert panel review in identifying a drug-induced liver injury (DILI) due to antituberculosis therapy (ATT) and/or...
2.
Geragotellis A, Patel S, Sonderup M, Wearne N, Barday Z, Sanglay L, et al.
S Afr Med J
. 2022 Feb;
112(2):13505.
PMID: 35139993
Background: Hepatitis B virus (HBV) remains endemic in South Africa (SA), with a concomitantly high prevalence of HIV co-infection. Chronic kidney disease in these subpopulations also has a high prevalence....
3.
Taylor-Robinson S, Morgan M, Spearman C, Suliman A, Corrah T, Oleribe O, et al.
QJM
. 2022 Jan;
115(3):191-192.
PMID: 35080615
No abstract available.
4.
Maughan D, Sonderup M, Gogela N, Locketz M, Wainwright H, Setshedi M, et al.
S Afr Med J
. 2021 Dec;
111(12):1190-1196.
PMID: 34949306
Background: Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, has been a component of first-line antiretroviral therapy (ART) in the South African HIV/AIDS programme since 2004. It is extensively used in...
5.
Taylor-Robinson S, Spearman C, Suliman A
QJM
. 2021 Jan;
114(6):357-358.
PMID: 33486529
Disproportionately few clinical trials are undertaken on the African continent, in part due to lingering neocolonial attitudes in the Global North which keep research activity primarily in developing countries, while...
6.
Sonderup M, Gogela N, Nordien R, Smuts H, Korsman S, Hardie D, et al.
S Afr Med J
. 2020 Jul;
110(2):112-117.
PMID: 32657680
Background: An estimated 600 000 South Africans are chronically infected with hepatitis C virus (HCV). To date, accurate prevalence data are lacking, but emerging data suggest a significant burden in...
7.
Nordien R, Sonderup M, Spearman C
S Afr Med J
. 2020 Jul;
110(2):106-111.
PMID: 32657679
Background: Hepatitis C virus (HCV) in South Africa (SA) is incompletely characterised and understood. Epidemiological and clinical data will better inform our understanding and assist national policy decision-making. Against the...
8.
Spearman C
S Afr Med J
. 2018 Sep;
108(8b):13-16.
PMID: 30182907
Hepatitis B (HBV) remains a global health problem despite the availability of effective vaccines since 1982 and effective antiviral therapy. The global burden of disease is substantial, with HBV resulting...
9.
Gogela N, Sonderup M, Rebe K, Chivese T, Spearman C
S Afr Med J
. 2018 Jul;
108(7):568-572.
PMID: 30004344
Background: Globally 1% of individuals are infected with hepatitis C virus (HCV). In South Africa (SA) the prevalence ranges between 0.3% and 1%, with few prospective screening data available. Similarly,...
10.
Gencay M, Seffner A, Pabinger S, Gautier J, Gohl P, Weizenegger M, et al.
J Viral Hepat
. 2018 Apr;
25(10):1132-1138.
PMID: 29660206
An important requirement for a state-of-the-art hepatitis B surface antigen (HBsAg) screening assay is reliable detection of mutated HBsAg. Currently, there is a striking shortage of data regarding the detection...